Log in

NASDAQ:AMLN - Amylin Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amylin Pharmaceuticals, Inc (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:AMLN
CUSIPN/A
Phone+1-858-5522200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive AMLN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMLN and its competitors with MarketBeat's FREE daily newsletter.


Amylin Pharmaceuticals (NASDAQ:AMLN) Frequently Asked Questions

What is Amylin Pharmaceuticals' stock symbol?

Amylin Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLN."

Has Amylin Pharmaceuticals been receiving favorable news coverage?

News articles about AMLN stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amylin Pharmaceuticals earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Amylin Pharmaceuticals.

What other stocks do shareholders of Amylin Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amylin Pharmaceuticals investors own include aTyr Pharma (LIFE), Alphabet (GOOG), Keurig Green Mountain (GMCR), First Solar (FSLR), EXACT Sciences (EXAS), Booking (BKNG), Arena Pharmaceuticals (ARNA), Ariad Pharmaceuticals (ARIA), Amarin (AMRN) and Aegerion Pharmaceuticals (AEGR).

What is Amylin Pharmaceuticals' official website?

The official website for Amylin Pharmaceuticals is http://www.amylin.com/.

How can I contact Amylin Pharmaceuticals?

Amylin Pharmaceuticals' mailing address is 9360 Towne Centre Dr Ste 110, SAN DIEGO, CA 92121-3030, United States. The biopharmaceutical company can be reached via phone at +1-858-5522200.


MarketBeat Community Rating for Amylin Pharmaceuticals (NASDAQ AMLN)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Amylin Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: Trading Ex-Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel